Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation. / Mathiasen, D.P.; Egebjerg, C.; Andersen, S.H.; Rafn, B.; Puustinen, P.; Khanna, A.; Daugaard, M.; Valo, E.; Tuomela, S.; Bøttzauw, T.; Nielsen, Christian Thomas Friberg; Willumsen, Berthe Marie; Hautaniemi, S.; Lahesmaa, R.; Westermarck, J.; Jäättelä, M.; Kallunki, T.

In: Oncogene, Vol. 31, 2012, p. 390-401.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Mathiasen, DP, Egebjerg, C, Andersen, SH, Rafn, B, Puustinen, P, Khanna, A, Daugaard, M, Valo, E, Tuomela, S, Bøttzauw, T, Nielsen, CTF, Willumsen, BM, Hautaniemi, S, Lahesmaa, R, Westermarck, J, Jäättelä, M & Kallunki, T 2012, 'Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation', Oncogene, vol. 31, pp. 390-401. https://doi.org/10.1038/onc.2011.230

APA

Mathiasen, D. P., Egebjerg, C., Andersen, S. H., Rafn, B., Puustinen, P., Khanna, A., Daugaard, M., Valo, E., Tuomela, S., Bøttzauw, T., Nielsen, C. T. F., Willumsen, B. M., Hautaniemi, S., Lahesmaa, R., Westermarck, J., Jäättelä, M., & Kallunki, T. (2012). Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation. Oncogene, 31, 390-401. https://doi.org/10.1038/onc.2011.230

Vancouver

Mathiasen DP, Egebjerg C, Andersen SH, Rafn B, Puustinen P, Khanna A et al. Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation. Oncogene. 2012;31:390-401. https://doi.org/10.1038/onc.2011.230

Author

Mathiasen, D.P. ; Egebjerg, C. ; Andersen, S.H. ; Rafn, B. ; Puustinen, P. ; Khanna, A. ; Daugaard, M. ; Valo, E. ; Tuomela, S. ; Bøttzauw, T. ; Nielsen, Christian Thomas Friberg ; Willumsen, Berthe Marie ; Hautaniemi, S. ; Lahesmaa, R. ; Westermarck, J. ; Jäättelä, M. ; Kallunki, T. / Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation. In: Oncogene. 2012 ; Vol. 31. pp. 390-401.

Bibtex

@article{47271835d98a4476b18aee1f6ef679bb,
title = "Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation",
abstract = "Ras is one of the most frequently activated oncogenes in cancer. Two mitogen-activated protein kinases (MAPKs) are important for ras transformation: extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase 2 (JNK2). Here we present a downstream signal amplification cascade that is critical for ras transformation in murine embryonic fibroblasts. This cascade is coordinated by ERK and JNK2 MAPKs, whose Ras-mediated activation leads to the enhanced levels of three oncogenic transcription factors, namely, c-Myc, activating transcription factor 2 (ATF2) and ATF3, all of which are essential for ras transformation. Previous studies show that ERK-mediated serine 62 phosphorylation protects c-Myc from proteasomal degradation. ERK is, however, not alone sufficient to stabilize c-Myc but requires the cooperation of cancerous inhibitor of protein phosphatase 2A (CIP2A), an oncogene that counteracts protein phosphatase 2A-mediated dephosphorylation of c-Myc. Here we show that JNK2 regulates Cip2a transcription via ATF2. ATF2 and c-Myc cooperate to activate the transcription of ATF3. Remarkably, not only ectopic JNK2, but also ectopic ATF2, CIP2A, c-Myc and ATF3 are sufficient to rescue the defective ras transformation of JNK2-deficient cells. Thus, these data identify the key signal converging point of JNK2 and ERK pathways and underline the central role of CIP2A in ras transformation.Oncogene advance online publication, 27 June 2011; doi:10.1038/onc.2011.230.",
author = "D.P. Mathiasen and C. Egebjerg and S.H. Andersen and B. Rafn and P. Puustinen and A. Khanna and M. Daugaard and E. Valo and S. Tuomela and T. B{\o}ttzauw and Nielsen, {Christian Thomas Friberg} and Willumsen, {Berthe Marie} and S. Hautaniemi and R. Lahesmaa and J. Westermarck and M. J{\"a}{\"a}ttel{\"a} and T. Kallunki",
year = "2012",
doi = "10.1038/onc.2011.230",
language = "English",
volume = "31",
pages = "390--401",
journal = "Oncogene",
issn = "0950-9232",
publisher = "nature publishing group",

}

RIS

TY - JOUR

T1 - Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation

AU - Mathiasen, D.P.

AU - Egebjerg, C.

AU - Andersen, S.H.

AU - Rafn, B.

AU - Puustinen, P.

AU - Khanna, A.

AU - Daugaard, M.

AU - Valo, E.

AU - Tuomela, S.

AU - Bøttzauw, T.

AU - Nielsen, Christian Thomas Friberg

AU - Willumsen, Berthe Marie

AU - Hautaniemi, S.

AU - Lahesmaa, R.

AU - Westermarck, J.

AU - Jäättelä, M.

AU - Kallunki, T.

PY - 2012

Y1 - 2012

N2 - Ras is one of the most frequently activated oncogenes in cancer. Two mitogen-activated protein kinases (MAPKs) are important for ras transformation: extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase 2 (JNK2). Here we present a downstream signal amplification cascade that is critical for ras transformation in murine embryonic fibroblasts. This cascade is coordinated by ERK and JNK2 MAPKs, whose Ras-mediated activation leads to the enhanced levels of three oncogenic transcription factors, namely, c-Myc, activating transcription factor 2 (ATF2) and ATF3, all of which are essential for ras transformation. Previous studies show that ERK-mediated serine 62 phosphorylation protects c-Myc from proteasomal degradation. ERK is, however, not alone sufficient to stabilize c-Myc but requires the cooperation of cancerous inhibitor of protein phosphatase 2A (CIP2A), an oncogene that counteracts protein phosphatase 2A-mediated dephosphorylation of c-Myc. Here we show that JNK2 regulates Cip2a transcription via ATF2. ATF2 and c-Myc cooperate to activate the transcription of ATF3. Remarkably, not only ectopic JNK2, but also ectopic ATF2, CIP2A, c-Myc and ATF3 are sufficient to rescue the defective ras transformation of JNK2-deficient cells. Thus, these data identify the key signal converging point of JNK2 and ERK pathways and underline the central role of CIP2A in ras transformation.Oncogene advance online publication, 27 June 2011; doi:10.1038/onc.2011.230.

AB - Ras is one of the most frequently activated oncogenes in cancer. Two mitogen-activated protein kinases (MAPKs) are important for ras transformation: extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase 2 (JNK2). Here we present a downstream signal amplification cascade that is critical for ras transformation in murine embryonic fibroblasts. This cascade is coordinated by ERK and JNK2 MAPKs, whose Ras-mediated activation leads to the enhanced levels of three oncogenic transcription factors, namely, c-Myc, activating transcription factor 2 (ATF2) and ATF3, all of which are essential for ras transformation. Previous studies show that ERK-mediated serine 62 phosphorylation protects c-Myc from proteasomal degradation. ERK is, however, not alone sufficient to stabilize c-Myc but requires the cooperation of cancerous inhibitor of protein phosphatase 2A (CIP2A), an oncogene that counteracts protein phosphatase 2A-mediated dephosphorylation of c-Myc. Here we show that JNK2 regulates Cip2a transcription via ATF2. ATF2 and c-Myc cooperate to activate the transcription of ATF3. Remarkably, not only ectopic JNK2, but also ectopic ATF2, CIP2A, c-Myc and ATF3 are sufficient to rescue the defective ras transformation of JNK2-deficient cells. Thus, these data identify the key signal converging point of JNK2 and ERK pathways and underline the central role of CIP2A in ras transformation.Oncogene advance online publication, 27 June 2011; doi:10.1038/onc.2011.230.

U2 - 10.1038/onc.2011.230

DO - 10.1038/onc.2011.230

M3 - Journal article

C2 - 21706057

VL - 31

SP - 390

EP - 401

JO - Oncogene

JF - Oncogene

SN - 0950-9232

ER -

ID: 33923758